These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 25397515)

  • 1. An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy.
    Cozzi-Lepri A; Antinori A; Bonora S; Cingolani A; Cassola G; Angarano G; Vullo V; Mussini C; Gori A; Maggiolo F; Castagna A;
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19771. PubMed ID: 25397515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort.
    d'Arminio Monforte A; Lorenzini P; Cozzi-Lepri A; Mussini C; Castagna A; Baldelli F; Puoti M; Vichi F; Maddaloni A; Lo Caputo S; Gianotti N; Antinori A;
    HIV Clin Trials; 2018 Apr; 19(2):52-60. PubMed ID: 29493419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy.
    Cozzi-Lepri A; Lo Caputo S; Maggiolo F; Antinori A; Ammassari A; Marchetti G; Mastroianni C; Gori A; Di Perri G; Angarano G; Carbone A; Monforte Ad;
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19775. PubMed ID: 25397519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment.
    Marcelin AG; Charpentier C; Wirden M; Descamps D; Calvez V
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19744. PubMed ID: 25397489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis.
    Zaccarelli M; Fabbiani M; Pinnetti C; Borghi V; Giannetti A; Sterrantino G; Lorenzini P; Latini A; Loiacono L; Colafigli M; Ammassari A; D'Ettorre G; Plazzi M; Di Giambenedetto S; Antinori A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19802. PubMed ID: 25397546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication.
    Pinnetti C; Lorenzini P; Cozzi-Lepri A; Sandrine O; Tommasi C; Zaccarelli M; Perno CF; Capobianchi MR; Girardi E; Antinori A; Ammassari A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19809. PubMed ID: 25397553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort.
    d'Arminio Monforte A; Cozzi-Lepri A; Maggiolo F; Rizzardini G; Manconi PE; Gianotti N; Quirino T; Pinnetti C; Rusconi S; De Luca A; Antinori A;
    PLoS One; 2016; 11(6):e0156360. PubMed ID: 27348592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO.
    Molina JM; Clotet B; van Lunzen J; Lazzarin A; Cavassini M; Henry K; Kulagin V; Givens N; Brennan C; de Oliveira CF
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19490. PubMed ID: 25393999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre.
    Borghetti A; Mondi A; Piccoli B; Gagliardini R; Lamonica S; Ciccarelli N; D'Avino A; Pallavicini F; Cauda R; De Luca A; Fabbiani M; Di Giambenedetto S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19817. PubMed ID: 25397561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort.
    Di Biagio A; Cozzi-Lepri A; Prinapori R; Angarano G; Gori A; Quirino T; De Luca A; Costantini A; Mussini C; Rizzardini G; Antinori A; Monforte AD;
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19825. PubMed ID: 25397569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008-2010.
    Jarrin I; Hernández-Novoa B; Alejos B; Riera M; Navarro G; Bernardino JI; Rivero M; del Amo J; Moreno S;
    Antivir Ther; 2013; 18(2):161-70. PubMed ID: 22997147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens.
    Giacomelli A; Oreni L; Franzetti M; Di Cristo V; Vergani B; Morosi M; Colella E; Galli M; Rusconi S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19830. PubMed ID: 25397574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort.
    Rokx C; Fibriani A; van de Vijver D; Verbon A; Schutten M; Gras L; Rijnders BJ
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19491. PubMed ID: 25394000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.
    Farr AM; Johnston SS; Ritchings C; Brouillette M; Rosenblatt L
    J Med Econ; 2016; 19(4):386-96. PubMed ID: 26640980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes.
    Elzi L; Erb S; Furrer H; Ledergerber B; Cavassini M; Hirschel B; Vernazza P; Bernasconi E; Weber R; Battegay M;
    Arch Intern Med; 2012 Sep; 172(17):1313-21. PubMed ID: 22892835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala.
    Laker E; Mambule I; Nalwanga D; Musaazi J; Kiragga A; Parkes-Ratanshi R
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19792. PubMed ID: 25397536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting.
    Farr AM; Johnston SS; Ritchings C; Brouillette M; Rosenblatt L
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19538. PubMed ID: 25394047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen.
    Jarrin I; Hernández-Novoa B; Alejos B; Santos I; Lopez-Aldeguer J; Riera M; Gutiérrez F; Rubio R; Antela A; Blanco JR; Moreno S;
    HIV Med; 2014 Oct; 15(9):547-56. PubMed ID: 24655804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Darunavir-based dual therapy in HIV experienced patients.
    Sterrantino G; Zaccarelli M; Di Biagio A; Rosi A; Bruzzone B; Cicconi P; Carli T; Biondi ML; Antinori A; Bartolozzi D; Penco G
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19782. PubMed ID: 25397526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.